Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists ; volume:38 ; number:16 ; day:30 ; month:8 ; year:2024 ; pages:3077-3086 ; date:11.2024
Eye ; 38, Heft 16 (30.8.2024), 3077-3086, 11.2024
- Urheber
-
Downey, Louise
Sivaprasad, Sobha
Chhabra, Ramandeep
Bailey, Clare
Chakrabarti, Soma
Elsherbiny, Samer
Patel, Jignesh
Silvestri, Giuliana
Watson, Sarah-Lucie
Williams, Gwyn
Parker, Antony
Khokhar, Saima
Lotery, Andrew J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41433-024-03223-w
- URN
-
urn:nbn:de:101:1-2501252105010.779027176029
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Downey, Louise
- Sivaprasad, Sobha
- Chhabra, Ramandeep
- Bailey, Clare
- Chakrabarti, Soma
- Elsherbiny, Samer
- Patel, Jignesh
- Silvestri, Giuliana
- Watson, Sarah-Lucie
- Williams, Gwyn
- Parker, Antony
- Khokhar, Saima
- Lotery, Andrew J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
Influence of macular oedema on the measurement of macular pigment optical density
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Pipeline therapies for neovascular age related macular degeneration
One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema
Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
Influence of macular oedema on the measurement of macular pigment optical density
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Pipeline therapies for neovascular age related macular degeneration
One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema
Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
Influence of macular oedema on the measurement of macular pigment optical density
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Pipeline therapies for neovascular age related macular degeneration
One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema
Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
Near-infrared reflectance imaging of neovascular age-related macular degeneration